Compare
Tempest Therapeutics, Inc. vs Lipocine Inc. vs Aditxt, Inc. vs Impact Biomedical Inc.
| Latest fiscal year | Tempest Therapeutics, Inc. TPST | Lipocine Inc. LPCN | Aditxt, Inc. ADTX | Impact Biomedical Inc. IBO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $1.98M | $3.2K | $32.0K |
| Revenue growth (YoY) | n/a | -82.3% | -97.6% | n/a |
| Gross margin | n/a | n/a | 8.4% | n/m (computed) |
| Operating margin | n/a | -524.7% | n/m | n/m |
| Net margin | n/a | -487.1% | n/m | n/m |
| Net income | -$26.26M | -$9.63M | -$43.10M | -$11.84M |
| EPS (Diluted) | -$6.33 | -$1.69 | -$1153.83 | -$0.38 |
| Operating cash flow | -$26.82M | -$9.76M | -$25.69M | -$1.89M |
| Free cash flow | -$26.82M | n/a | -$25.70M | n/a |
| Cash & equivalents | $7.71M | $5.21M | n/a | $3.0K |
| Total assets | $16.93M | $17.01M | $16.52M | $17.41M |
| Total liabilities | $10.26M | $2.53M | $12.56M | $1.85M |
| Shareholders' equity | $6.67M | $14.48M | $5.61M | $12.61M |
| Return on year-end equity | -393.9% | -66.5% | -768.3% | -93.9% |
| Shares outstanding | 4.93M | 6.16M | 411.5K | 104.62M |
Revenue, most recent five fiscal years
| Fiscal year | Tempest Therapeutics, Inc. | Lipocine Inc. | Aditxt, Inc. | Impact Biomedical Inc. |
|---|---|---|---|---|
| Latest | $295.0K Ended 2017-12-31 | $1.98M Ended 2025-12-31 | $3.2K Ended 2025-12-31 | $32.0K Ended 2025-12-31 |
| 1 year earlier | $653.0K Ended 2016-12-31 | $11.20M Ended 2024-12-31 | $134.0K Ended 2024-12-31 | n/a |
| 2 years earlier | $277.0K Ended 2015-12-31 | -$2.85M Ended 2023-12-31 | $645.2K Ended 2023-12-31 | n/a |
| 3 years earlier | $0 Ended 2014-12-31 | $500.0K Ended 2022-12-31 | $933.7K Ended 2022-12-31 | $50.0K Ended 2022-12-31 |
| 4 years earlier | $0 Ended 2013-12-31 | $16.14M Ended 2021-12-31 | $105.0K Ended 2021-12-31 | n/a |